Cellipont Bioservices has completed an expansion of its manufacturing capabilities with the addition of a new ballroom-style cleanroom with a 50 litre single-use bioreactor at its facility in Texas.
“Our newest cleanroom and 50 litre single-use bioreactor represent a significant milestone in our commitment to supporting the next generation of cell therapies,” said Darren Head, CEO of Cellipont Bioservices.
The upgrade is supported by an investment from Cellipoint Bioservices to support advanced manufacturing of allogeneic cell therapies, such as exosome, iPSC, and MSC-based therapies.
Allogeneic therapies utilise cells, tissues or genes from a donor to enable faster mass production and off-the-shelf availability.
The cell therapies are used to treat conditions like leukaemia or lymphoma, blood or immune disorders and other conditions.
The facility is part of a broader manufacturing infrastructure of the 76,000 sqft manufacturing site in The Woodlands.
The ballroom-style cleanroom provides flexible, high-throughput bioprocessing space designed to accommodate multiple client programs and evolving manufacturing technologies.
It also features a 50 litre single-use bioreactor that enables smoother transition from early-stage process development to larger, more consistent batches suitable for late-stage clinical programmes and commercial readiness.
Cellipont says the expansion will enhance its ability to offer fully integrated services spanning process development, analytical support and cGMP manufacturing for advanced therapies.